よむ、つかう、まなぶ。
【参考資料２－２】抗微生物薬適正使用の手引き 第四版（案）医科・入院編 (43 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第四版
医科・入院編
1
2
3
54. Bailly S, et al. Antifungal de-escalation was not associated with adverse outcome in
critically ill patients treated for invasive candidiasis: post hoc analyses of the
AmarCAND2 study data. Intensive care Med. 2015. 41(11):1931-1940.
4
5
6
55. Seddon MM, et al. Role of Early De-escalation of Antimicrobial Therapy on Risk of
Clostridioides difficile Infection Following Enterobacteriaceae Bloodstream Infections.
Clin Infect Dis. 2019. 69(3):414-420.
7
8
9
56. Lew KY, et al. Safety and clinical outcomes of carbapenem de-escalation as part of an
antimicrobial stewardship programme in an ESBL-endemic setting. J Antimicrobial
Chemother. 2015. 70(4):1219-1225.
10
11
12
57. Tagashira Y, et al. Antimicrobial stewardship for carbapenem use at a Japanese tertiary
care center: An interrupted time series analysis on the impact of infectious disease
consultation, prospective audit, and feedback. Am J Infect Control. 2016. 44(6):708-710.
13
14
15
58. Honda H, et al. Efficacy of a Postprescription Review of Broad-Spectrum Antimicrobial
Agents With Feedback: A 4-Year Experience of Antimicrobial Stewardship at a Tertiary
Care Center. Open Forum Infect Dis. 2018. 5(12):ofy314.
16
17
18
59. Akazawa T, et al. Eight-Year Experience of Antimicrobial Stewardship Program and the
Trend of Carbapenem Use at a Tertiary Acute-Care Hospital in Japan-The Impact of
Postprescription Review and Feedback. Open Forum Infect Dis. 2019. 6(10):ofz389.
19
20
60. Morgan DJ, et al. Shorter Courses of Antibiotics for Urinary Tract Infection in Men.
JAMA. 2021. 326(4):309-310.
21
22
61. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial
resistance in 2019: a systematic analysis. Lancet. 2022. 399(10325):629-655.
23
24
62. Ramirez J, et al. Antibiotics as Major Disruptors of Gut Microbiota. Front Cell Infect
Microbiol. 2020. 10:572912.
25
26
27
63. Esaiassen E, et al. Antibiotic exposure in neonates and early adverse outcomes: a
systematic review and meta-analysis. J Antimicrob Chemother. 2017 Jul;72(7):18581870,
28
29
30
64. Lee RA, et al. Appropriate Use of Short-Course Antibiotics in Common Infections: Best
Practice Advice from the American College of Physicians. Ann Intern Med. 2021.
174(6):822-827.
31
32
33
65. Abbas M, et al. Association between treatment duration and mortality or relapse in adult
patients with Staphylococcus aureus bacteraemia: a retrospective cohort study. Clin
Microbiol Infect, 2020. 26(5):626-631.
34
35
36
66. Lafaurie M, et al. Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men:
A Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Clin Infect Dis. 2023. 76(12):2154-2162.
37
38
67. Bernard L, et al. Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection. N
Engl J Med. 2021. 384(21):1991-2001.
39
40
41
68. Sehgal I, et al. Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole
to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised
controlled trial in India, Lancet Infect Dis. 2022. 22(7):1052-1061.
42
43
44
45
46
47
69. BALANCE Investigators, for the Canadian Critical Care Trials Group, the Association of
Medical Microbiology and Infectious Disease Canada Clinical Research Network, the
Australian and New Zealand Intensive Care Society Clinical Trials Group, and the
Australasian Society for Infectious Diseases Clinical Research Network; Daneman N, et
al. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections. N
Engl J Med. 2025. 392(11):1065-1078.
43
第四版
医科・入院編
1
2
3
54. Bailly S, et al. Antifungal de-escalation was not associated with adverse outcome in
critically ill patients treated for invasive candidiasis: post hoc analyses of the
AmarCAND2 study data. Intensive care Med. 2015. 41(11):1931-1940.
4
5
6
55. Seddon MM, et al. Role of Early De-escalation of Antimicrobial Therapy on Risk of
Clostridioides difficile Infection Following Enterobacteriaceae Bloodstream Infections.
Clin Infect Dis. 2019. 69(3):414-420.
7
8
9
56. Lew KY, et al. Safety and clinical outcomes of carbapenem de-escalation as part of an
antimicrobial stewardship programme in an ESBL-endemic setting. J Antimicrobial
Chemother. 2015. 70(4):1219-1225.
10
11
12
57. Tagashira Y, et al. Antimicrobial stewardship for carbapenem use at a Japanese tertiary
care center: An interrupted time series analysis on the impact of infectious disease
consultation, prospective audit, and feedback. Am J Infect Control. 2016. 44(6):708-710.
13
14
15
58. Honda H, et al. Efficacy of a Postprescription Review of Broad-Spectrum Antimicrobial
Agents With Feedback: A 4-Year Experience of Antimicrobial Stewardship at a Tertiary
Care Center. Open Forum Infect Dis. 2018. 5(12):ofy314.
16
17
18
59. Akazawa T, et al. Eight-Year Experience of Antimicrobial Stewardship Program and the
Trend of Carbapenem Use at a Tertiary Acute-Care Hospital in Japan-The Impact of
Postprescription Review and Feedback. Open Forum Infect Dis. 2019. 6(10):ofz389.
19
20
60. Morgan DJ, et al. Shorter Courses of Antibiotics for Urinary Tract Infection in Men.
JAMA. 2021. 326(4):309-310.
21
22
61. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial
resistance in 2019: a systematic analysis. Lancet. 2022. 399(10325):629-655.
23
24
62. Ramirez J, et al. Antibiotics as Major Disruptors of Gut Microbiota. Front Cell Infect
Microbiol. 2020. 10:572912.
25
26
27
63. Esaiassen E, et al. Antibiotic exposure in neonates and early adverse outcomes: a
systematic review and meta-analysis. J Antimicrob Chemother. 2017 Jul;72(7):18581870,
28
29
30
64. Lee RA, et al. Appropriate Use of Short-Course Antibiotics in Common Infections: Best
Practice Advice from the American College of Physicians. Ann Intern Med. 2021.
174(6):822-827.
31
32
33
65. Abbas M, et al. Association between treatment duration and mortality or relapse in adult
patients with Staphylococcus aureus bacteraemia: a retrospective cohort study. Clin
Microbiol Infect, 2020. 26(5):626-631.
34
35
36
66. Lafaurie M, et al. Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men:
A Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Clin Infect Dis. 2023. 76(12):2154-2162.
37
38
67. Bernard L, et al. Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection. N
Engl J Med. 2021. 384(21):1991-2001.
39
40
41
68. Sehgal I, et al. Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole
to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised
controlled trial in India, Lancet Infect Dis. 2022. 22(7):1052-1061.
42
43
44
45
46
47
69. BALANCE Investigators, for the Canadian Critical Care Trials Group, the Association of
Medical Microbiology and Infectious Disease Canada Clinical Research Network, the
Australian and New Zealand Intensive Care Society Clinical Trials Group, and the
Australasian Society for Infectious Diseases Clinical Research Network; Daneman N, et
al. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections. N
Engl J Med. 2025. 392(11):1065-1078.
43